TY - JOUR
T1 - Angiogenic impairment of the vascular endothelium
T2 - A novel mechanism and potential therapeutic target in muscular dystrophy
AU - Palladino, Mariangela
AU - Gatto, Ilaria
AU - Neri, Valentina
AU - Straino, Stefania
AU - Smith, Roy C.
AU - Silver, Marcy
AU - Gaetani, Eleonora
AU - Marcantoni, Margherita
AU - Giarretta, Igor
AU - Stigliano, Egidio
AU - Capogrossi, Maurizio
AU - Hlatky, Lynn
AU - Landolfi, Raffaele
AU - Pola, Roberto
PY - 2013/12
Y1 - 2013/12
N2 - OBJECTIVE - : Dystrophin, the missing or defective protein in Duchenne muscular dystrophy, is expressed not only in muscle cells but also in vascular endothelial cells (ECs). In this study, we assessed the effects of dystrophin deficiency on the angiogenic capacities of ECs. APPROACH AND RESULTS - : We isolated vascular ECs from mdx mice, the murine equivalent of Duchenne muscular dystrophy in humans, and wild-type controls, and we found that mdx-derived ECs have impaired angiogenic properties, in terms of migration, proliferation, and tube formation. They also undergo increased apoptosis in vitro compared with wild-type cells and have increased senescence-associated β-galactosidase activity. Mdx-derived ECs also display reduced ability to support myoblast proliferation when cocultured with satellite cell-derived primary myoblasts. These endothelial defects are mirrored by systemic impairment of angiogenesis in vivo, both on induction of ischemia, stimulation with growth factors in the corneal model and matrigel plug assays, and tumor growth. We also found that dystrophin forms a complex with endothelial NO synthase and caveolin-1 in ECs, and that NO production and cGMP formation are compromised in ECs isolated from mdx mice. Interestingly, treatment with aspirin enhances production of both cGMP and NO in dystrophic ECs, whereas low-dose aspirin improves the dystrophic phenotype of mdx mice in vivo, in terms of resistance to physical exercise, muscle fiber permeability, and capillary density. CONCLUSIONS - : These findings demonstrate that impaired angiogenesis is a novel player and potential therapeutic target in Duchenne muscular dystrophy.
AB - OBJECTIVE - : Dystrophin, the missing or defective protein in Duchenne muscular dystrophy, is expressed not only in muscle cells but also in vascular endothelial cells (ECs). In this study, we assessed the effects of dystrophin deficiency on the angiogenic capacities of ECs. APPROACH AND RESULTS - : We isolated vascular ECs from mdx mice, the murine equivalent of Duchenne muscular dystrophy in humans, and wild-type controls, and we found that mdx-derived ECs have impaired angiogenic properties, in terms of migration, proliferation, and tube formation. They also undergo increased apoptosis in vitro compared with wild-type cells and have increased senescence-associated β-galactosidase activity. Mdx-derived ECs also display reduced ability to support myoblast proliferation when cocultured with satellite cell-derived primary myoblasts. These endothelial defects are mirrored by systemic impairment of angiogenesis in vivo, both on induction of ischemia, stimulation with growth factors in the corneal model and matrigel plug assays, and tumor growth. We also found that dystrophin forms a complex with endothelial NO synthase and caveolin-1 in ECs, and that NO production and cGMP formation are compromised in ECs isolated from mdx mice. Interestingly, treatment with aspirin enhances production of both cGMP and NO in dystrophic ECs, whereas low-dose aspirin improves the dystrophic phenotype of mdx mice in vivo, in terms of resistance to physical exercise, muscle fiber permeability, and capillary density. CONCLUSIONS - : These findings demonstrate that impaired angiogenesis is a novel player and potential therapeutic target in Duchenne muscular dystrophy.
KW - Angiogenesis inhibitors
KW - Endothelium, vascular
KW - Muscle diseases, inflammatory
KW - Nitric oxide synthase type III
UR - http://www.scopus.com/inward/record.url?scp=84888199909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888199909&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.112.301172
DO - 10.1161/ATVBAHA.112.301172
M3 - Article
C2 - 24072696
AN - SCOPUS:84888199909
VL - 33
SP - 2867
EP - 2876
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
SN - 1079-5642
IS - 12
ER -